Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Community
/
United States
/
Healthcare
/
Zynex
ZYXI
Zynex
Regulatory And Reimbursement Issues Will Limit Revenue While Operations Stabilize
AN
AnalystLowTarget
Not Invested
Consensus Narrative from 2 Analysts
Published
30 May 25
Updated
09 Aug 25
0
Set Fair Value
0
votes
Share
AnalystLowTarget
's Fair Value
US$2.00
20.5% undervalued
intrinsic discount
09 Aug
US$1.59
Loading
1Y
-78.7%
7D
8.2%
Author's Valuation
US$2.0
20.5% undervalued
intrinsic discount
AnalystLowTarget Fair Value
View Valuation
Narrative
Updates
0
Valuator
Company Info
Notes
AnalystLowTarget Fair Value
US$2.0
20.5% undervalued
intrinsic discount
Future estimation in
3 Years
time period
Past
Future
-29m
194m
2014
2017
2020
2023
2025
2026
2028
Revenue US$111.2m
Earnings US$13.7m
Revenue
Profit Margin
Future PE
Revenue
% p.a.
0
Decrease
Increase
Current revenue growth rate
0.16%
Medical Equipment revenue growth rate
0.44%
Other Inputs & Calculation
Risk Level (Discount Rate)
Our default considers factors like the company's size, volatility, profitablity and country of operation.
Risk Level (Discount Rate)
%
0
Decrease
Increase
Current discount rate
10.77%
Calculation
US$13.73m
Earnings '28
x
5.20x
PE Ratio '28
=
US$71.37m
Market Cap '28
US$71.37m
Market Cap '28
/
26.35m
No. shares '28
=
US$2.71
Share Price '28
US$2.71
Share Price '28
Discounted to 2025 @ 11.13% p.a.
=
US$1.97
Fair Value '25
